Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $340.00, for a total transaction of $680,000.00. Following the transaction, the director now directly owns 14,000 shares in the company, valued at approximately $4,760,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Regeneron Pharmaceuticals Inc (REGN) traded down $6.49 on Thursday, reaching $334.93. 569,516 shares of the company traded hands, compared to its average volume of 1,120,000. Regeneron Pharmaceuticals Inc has a 12 month low of $313.53 and a 12 month high of $543.55. The company has a market capitalization of $35,980.00, a PE ratio of 25.49, a PEG ratio of 1.06 and a beta of 1.54. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the business posted $3.04 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 28.9% on a year-over-year basis. analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC increased its position in Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 307 shares during the last quarter. Pin Oak Investment Advisors Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $152,000. Advisory Services Network LLC increased its position in Regeneron Pharmaceuticals by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 266 shares during the last quarter. Vident Investment Advisory LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth $200,000. Finally, Mackenzie Financial Corp bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $204,000. Institutional investors own 66.40% of the company’s stock.
REGN has been the topic of several analyst reports. Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a report on Thursday, November 16th. BTIG Research reiterated a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, November 27th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Finally, Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $480.00 to $380.00 in a research report on Friday, December 1st. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $449.49.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.